Searchable abstracts of presentations at key conferences in endocrinology

ea0014p284 | (1) | ECE2007

ESR2 genotypes are associated with a reduced relative risk for sporadic colorectal cancer

Martineti Valentina , Picariello Lucia , Del Monte Francesca , Valanzano Rosa , Strigoli Debora , Sala Silvia Carbonell , Canonico Giuseppe , Tonelli Francesco , Brandi Maria Luisa

According to incidence data from Italian cancer registers, colorectal cancer is the third most common cancer in both men and women even considering skin non-melanoma cancers, lung and breast cancers. Moreover it represents the third absolute leading cause of cancer death in women and the fourth in men. Although data on Italian population regarding the role of estrogens in colorectal cancer have not yet been collected, several strands of evidence from international epidemiologi...

ea0081p557 | Calcium and Bone | ECE2022

Hyperparathyroidism development after oncogenic osteomalacia treatment

Patera Bohdan , Martina Bianchi Federica , Clementi Ilaria , Maria Fazzino Gaia Francesca , Lanzo Nicola , Lepanto Silvia , Manzella La Barbera Francesca , Piantanida Eliana , Tanda Maria Laura

Tumor-induced osteomalacia (TIO) or ‘oncogenic osteomalacia’ is a rare paraneoplastic disorder, usually resulting from Fibroblast Growth Factor 23 (FGF23) oversecretion by a benign small ‘phosphaturic mesenchymal tumor’, causing hypophosphatemia and reduced 1,25-dihydroxyvitamin D synthesis. Calcium and parathyroid hormone (PTH) levels are usually normal, but secondary/tertiary hyperparathyroidism has been reported in up to 5% of the cases, mainly due to 1,...

ea0081ep13 | Adrenal and Cardiovascular Endocrinology | ECE2022

A challenging case of hypertension: an ACTH-secreting pheochromocytoma

Lanzo Nicola , Fazzino Gaia Francesca Maria , La Barbera Francesca Manzella , Patera Bohdan , Lepanto Silvia , Bianchi Federica Martina , Clementi Ilaria , Piantanida Eliana , Tanda Maria Laura

Pheochromocytoma is a rare catecholamine-secreting tumour arising from chromaffin cells in the adrenal medulla and one of the main causes of endocrine hypertension. We here report the case of a 48-year old man admitted to the Internal Medicine Department for evaluation of resistant hypertension. The patient presented with headache, sweating, palpitations, pitting edema, hypertension and hypokalemia both resistant to conventional polytherapy. He was therefore investigated for e...

ea0090p658 | Endocrine-related Cancer | ECE2023

Cellular models of parathyroid carcinoma: preliminary results

Palmini Gaia , Marini Francesca , Giusti Francesca , Donati Simone , Aurilia Cinzia , Falsetti Irene , Zonefrati Roberto , Perigli Giuliano , Santoro Roberto , Nesi Gabriella , Luisa Brandi Maria

Parathyroid carcinoma (PC) is an extremely rare endocrine malignancy of the parathyroid glands, representing less than 1% of all parathyroid neoplasms. PC is characterized by an excessive secretion of parathyroid hormone (PTH) and severe hypercalcemia. In contrast to parathyroid adenoma, the prognosis for patients with PC is poor, with an overall survival rate of 78-85% and 49-70% respectively at 5 and 10 years after diagnosis, due to the commonly unmanageable hypercalcaemia, ...

ea0067o14 | Oral Presentations | EYES2019

Effects of thyroid function on peripheral serum markers: results from a cohort of thyroid cancer patients

Monzani Maria Laura , De Vincentis Sara , Della Casa Venturelli Francesca , Piccinini Francesca , Tagliavini Simonetta , Peeters Robin P , Simoni Manuela , Brigante Giulia

Objective: The aim of this study was to identify changes in thyroid hormone metabolism occurring in different thyroid functional states and to evaluate tissue response to thyroid hormone changes.Methods: Two hundred subjects (137 F, 63 M, mean age: 50.3±14.4 years) waiting to be treated or treated with total thyroidectomy for differentiated thyroid cancer were enrolled in this study. Thyroid function was investigated measuring TSH, fT4 and fT3, and ...

ea0063p1205 | Thyroid 3 | ECE2019

Quality of life in patients thyroidectomized for differentiated thyroid cancer

Laura Monzani Maria , De Vincentis Sara , Della Casa Venturelli Francesca , Piccinini Francesca , Tagliavini Simonetta , Peeters Robin P. , Simoni Manuela , Brigante Giulia

Background: The evaluation of health-related Quality of Life (QoL) is becoming a key component in clinical assessment of thyreopathic patients, especially those thyroidectomized for differentiated thyroid cancer (DTC) and treated with levothyroxine (LT4).Aim: To evaluate QoL in different thyroid states in patients treated with total thyroidectomy for DTC and correlate it with thyroid function tests.Methods: Two hundred subjects (13...

ea0037ep867 | Thyroid cancer | ECE2015

The two tyrosine kinase inhibitors, CLM29 and CLM3, have antineoplastic activity in primary cultures from anaplastic thyroid cancer obtained from fine needle aspiration

Ferrari Silvia Martina , Fallahi Poupak , Motta Concettina La , Materazzi Gabriele , Ragusa Francesca , Limongi Francesca , Ruffilli Ilaria , Settimo Federico Da , Miccoli Paolo , Antonelli Alessandro

Anaplastic thyroid cancer (ATC) is one of the most lethal endocrine malignancy, with a mean survival of about 6 months. Until now, the most effective therapy for ATC comprises a multimodal treatment protocol, including surgery, chemotherapy (doxorubicin and cisplatin), and hyperfractionated accelerated external beam radiotherapy, with a median patient survival of 10 months. A possible increase in the effectiveness of the treatment could be achieved testing the sensitivity of &...

ea0032p561 | Endocrine tumours and neoplasia | ECE2013

Everolimus treatment in a series of patients with advanced neuroendocrine tumors

Iacovazzo Donato , Lugli Francesca , Plastino Francesca , Schinzari Giovanni , Bianchi Antonio , Fusco Alessandra , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Barone Carlo Antonio Mario

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...

ea0022p422 | Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Juvenile hypertension due to coexistence of two very rare etiologies

Paragliola Rosa Maria , Ianni Francesca , Ricciato Maria Pia , Rosa Annapina De , Gallo Francesca , Locantore Pietro , Senes Paola , Rota Carlo Antonio , Pontecorvi Alfredo , Corsello Salvatore Maria

The coexistence of pheochromocytoma and hyperreninemia secondary to renal artery stenosis, which both represent important causes of juvenile hypertension, has been reported in Literature, while association between pheochromocytoma and reninoma has never been described.We evaluated a 24-year-old boy, which came to our attention for severe hypertension, unresponsive to anti-hypertensive polytherapy. In 1996, because of elevated calcitonin levels (180 pg/ml...

ea0035s20.1 | New hormones and endocrine tissues | ECE2014

FGF21, irisin and other novel players in endocrine metabòlic regulation

Villarroya Francesc , Cereijo Ruben , Villarroya Joan , Giralt Marta

Brown adipose tissue (BAT) activity is a relevant component of energy expenditure in mammals. Moreover, BAT constitutes an active site of glucose and lipid draining and, therefore, BAT activity is also a relevant actor in the control of glycemia and lipidemia. Recent years, possibly because of the awareness that active BAT is present in adult humans, have witnessed a burst in the identification of novel endocrine factors released by peripheral tissues that can act on BAT beyon...